Clairo

Generates clinical evidence for trials

London, England, United Kingdom

About Clairo

Clario specializes in generating clinical evidence for medical research by utilizing a comprehensive technology platform. Their services support various types of clinical trials, including decentralized, hybrid, and site-based trials. Clario's approach combines nearly 50 years of experience with a vast network of facilities across nine countries, allowing them to conduct a significant number of clinical trials and regulatory approvals. What sets Clario apart from competitors is their extensive expertise and the ability to provide a wide range of endpoint technologies, which enhances the quality of evidence produced. The company's goal is to empower partners in the healthcare industry to improve patient outcomes through reliable and rich clinical data.

London, United KingdomHeadquarters
1972Year Founded
$29.9MTotal Funding
GROWTH_EQUITY_VCCompany Stage
Biotechnology, HealthcareIndustries
5,001-10,000Employees

Benefits

Competitive and equitable total rewards package
Physical, mental and financial health and wellness
Flexible working approach

Risks

Increased competition from AI-driven platforms like Medable may threaten Clario's market share.
The IPO filing may lead to investor pressure for rapid financial returns, affecting strategy.
AI integration from ArtiQ poses data privacy and compliance risks, especially in the EU.

Differentiation

Clario offers a comprehensive endpoint technology platform for diverse clinical trial models.
The company has nearly 50 years of experience in clinical trial technology solutions.
Clario's global presence includes 30 facilities across North America, Europe, and Asia Pacific.

Upsides

Clario's IPO aims for a valuation of over $10 billion, indicating strong market confidence.
The FDA clearance of SpiroSphere® with wireless ECG enhances Clario's clinical trial capabilities.
Clario's acquisition of ArtiQ boosts its AI capabilities in respiratory clinical trials.